122 related articles for article (PubMed ID: 36372140)
1. Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.
Tang Y; Yang D; Xie R; Zhong Z; You Y
Transpl Immunol; 2023 Feb; 76():101743. PubMed ID: 36372140
[TBL] [Abstract][Full Text] [Related]
2. The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation.
Zhao XS; Wang Y; Yan CH; Wang JZ; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Transplant; 2014 Aug; 28(8):926-34. PubMed ID: 24931494
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor-α receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT].
Liu DY; Yan S; Ma DD; Zhang C; Fu KB; Liu XM; Liu XH; Wang Y; Li XQ; Zhang JQ; Xiu YY; Peng XJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):743-748. PubMed ID: 33113606
[No Abstract] [Full Text] [Related]
6. [Effect of ruxolitinib combined with glucocorticoid on cytomegalovirus activation in acute graft-versus-host disease].
Xing SY; Qian K; Zhao YX; Peng B; Yang JJ; Dou LP; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):732-737. PubMed ID: 36709166
[No Abstract] [Full Text] [Related]
7. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
8. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
9. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
10. Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
Eefting M; von dem Borne PA; de Wreede LC; Halkes CJ; Kersting S; Marijt EW; Veelken H; Falkenburg JF
Haematologica; 2014 Apr; 99(4):751-8. PubMed ID: 24241493
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
Meng G; Wang J; Wang X; Wang Y; Wang Z
Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study on the relapsd leukemia patients with graft versus host disease after allogeneic hematopoietic stem cell transplantation].
Zhang XH; Fu HX; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Zhao T; Wang Y; Chen Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):323-7. PubMed ID: 21122312
[TBL] [Abstract][Full Text] [Related]
15. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
16. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis].
Song AX; Yang DL; Wei JL; Yan ZS; Wang M; Jiang EL; Huang Y; Liu QG; Ma QL; Zhai WH; Zhang RL; Feng SZ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):161-6. PubMed ID: 20137139
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Outcomes and Prognostic Factors of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
Lou D; Liu L; Yan XQ; Gu FN; Zhang YP; Qin WW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1577-1585. PubMed ID: 36208269
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
[TBL] [Abstract][Full Text] [Related]
20. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]